ARK Invest has moved its ARK Venture Fund, which holds stakes in private AI companies like OpenAI and Anthropic, onto the Ethereum blockchain via Securitize. This tokenization aims to democratize access to private AI investments by recording ownership digitally onchain. However, the fund's shares remain illiquid as they are not listed on any exchange and can only be sold during limited redemption windows, which may be oversubscribed. This structure suits investors seeking long-term exposure to private AI firms and willing to accept manager-set valuations and limited liquidity.
ARK Invest's blockchain fund tokenizes private AI stakes. For readers following Technology-sector US stocks, here is Pluang's market snapshot as of Sep 29, 2026 23:41 WIB: out of 150 stocks, 70 rose and 80 fell. ASX rose 3.61% to USD 45.37 with 64% sell orders, HUBS fell 3.27% to USD 196.52 with 64% sell orders, and ASAN dropped 3.13% to USD 8.37 with a typical hold time of 35 days.
Precision Optics Corporation reported a strong Q4 with record revenue of $8.8 million, a 42% increase year-over-year, surpassing analyst estimates of $7.1 million. The company also beat EPS expectations, posting -$0.01 versus the predicted -$0.06, si...
Analyst firm Craig-Hallum adjusted Boot Barn Holdings' price target to $224, an 84.91% increase from its recent stock price of $121.14, reflecting strong growth potential. The company aims to expand merchandise margins by 60 basis points in fiscal 20...
Traders on prediction platforms Kalshi and Polymarket estimate a nearly 60% chance that the US added more than 90,000 jobs in September, with about a 50-50 chance of surpassing 100,000 jobs. This outlook is more optimistic than the Dow Jones economis...
GameStop's stock surged 31% in the past month, driven by CEO Ryan Cohen's significant personal share purchases, even as the overall gaming sector declined. While the VanEck Video Gaming and eSports ETF dropped 2%, and major peers like Take-Two Intera...
Inventiva announced improved financial results for the first half of 2026, reducing its net loss to €69.5 million from €175.9 million the previous year. The company completed the final patient visit in its Phase 3 NATiV3 trial for MASH, with topline ...
